Accurately quantified plasma free glycine concentration as a biomarker in patients with acute ischemic stroke

Wang, Huan; Ni, Xiaoyu; Dong, Weichong; Qin, Weiman; Xu, Lei; Jiang, Ye

doi:10.1007/s00726-023-03236-x

Cited by 2 publications

(2 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main marker for HIE that we have identified is glycine, which is consistent with clinical data for newborns with HIE [52,53]. Also, an increase in glycine has been described for models of global brain ischemia [53][54][55] and for patients in the acute phase of stroke in both plasma and cerebrospinal fluid [56,57]. We suggest that the main source of glycine could be a product of NADH synthesis reaction from serine under hypoxic conditions [58].…”

Section: Discussionsupporting

confidence: 87%

Metabolite Biomarkers for Early Ischemic Hypoxic Encephalopathy: An Experimental Study Using the NeoBase 2 MSMS Kit in a Rat Model

Shevtsova,

Starodubtseva,

Tokareva

et al. 2023

Preprint

View full text Add to dashboard Cite

Hypoxic-ischemic encephalopathy (HIE) is one of the most common causes of childhood disability. Hypothermic therapy is currently the only approved neuroprotective approach. However, early diagnosis of HIE can be challenging, especially in the first hours after birth when the decision to treat with hypothermic therapy is critical. Differentiating HIE from other neonatal conditions, such as sepsis, further complicates the diagnosis. This study investigated the utility of a metabolomic-based approach using the NeoBase 2 MSMS kit to diagnose HIE using dry blood stains in a Rice-Vannucci model of HIE in rats. We evaluated the diagnostic accuracy of this method between 3 and 6 hours after the onset of HIE, including in the context of systemic inflammation and concomitant hypothermic therapy. Discriminant analysis revealed several metabolite patterns associated with HIE. A logistic regression model using glycine levels achieved high diagnostic accuracy with areas under the curve (AUC) of 0.94 at 3 hours and 0.96 at 6 hours after the onset of HIE. In addition, orthogonal partial least squares discriminant analysis, which included five metabolites, achieved 100% sensitivity and 80% specificity within 3 hours of HIE. These results highlight the significant potential of the NeoBase 2 MSMS kit for the early diagnosis of HIE and could improve patient management and outcomes in this serious illness.

show abstract

Section: Discussionsupporting

confidence: 87%

Metabolite Biomarkers for Early Ischemic Hypoxic Encephalopathy: An Experimental Study Using the NeoBase 2 MSMS Kit in a Rat Model

Shevtsova,

Starodubtseva,

Tokareva

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The main marker for HIE that we have identified is glycine, which is consistent with clinical data for newborns with HIE [50,51]. Also, an increase in glycine has been described for models of global brain ischemia [51][52][53] and for patients in the acute phase of stroke in both plasma and cerebrospinal fluid [54,55]. We suggest that the main source of glycine could be a product of reduced nicotinamide adenine dinucleotide (NADH) synthesis reaction from serine under hypoxic conditions [56].…”

Section: Discussionsupporting

confidence: 85%

Metabolite Biomarkers for Early Ischemic–Hypoxic Encephalopathy: An Experimental Study Using the NeoBase 2 MSMS Kit in a Rat Model

Shevtsova,

Starodubtseva,

Tokareva

et al. 2024

IJMS

View full text Add to dashboard Cite

Hypoxic–ischemic encephalopathy (HIE) is one of the most common causes of childhood disability. Hypothermic therapy is currently the only approved neuroprotective approach. However, early diagnosis of HIE can be challenging, especially in the first hours after birth when the decision to use hypothermic therapy is critical. Distinguishing HIE from other neonatal conditions, such as sepsis, becomes a significant problem in diagnosis. This study explored the utility of a metabolomic-based approach employing the NeoBase 2 MSMS kit to diagnose HIE using dry blood stains in a Rice–Vannucci model of HIE in rats. We evaluated the diagnostic fidelity of this approach in a range between 3 and 6 h after the onset of HIE, including in the context of systemic inflammation and concomitant hypothermic therapy. Discriminant analysis revealed several metabolite patterns associated with HIE. A logistic regression model using glycine levels achieved high diagnostic fidelity with areas under the receiver operating characteristic curve of 0.94 at 3 h and 0.96 at 6 h after the onset of HIE. In addition, orthogonal partial least squares discriminant analysis, which included five metabolites, achieved 100% sensitivity and 80% specificity within 3 h of HIE. These results highlight the significant potential of the NeoBase 2 MSMS kit for the early diagnosis of HIE and could improve patient management and outcomes in this serious illness.

show abstract

Accurately quantified plasma free glycine concentration as a biomarker in patients with acute ischemic stroke

Cited by 2 publications

References 62 publications

Metabolite Biomarkers for Early Ischemic Hypoxic Encephalopathy: An Experimental Study Using the NeoBase 2 MSMS Kit in a Rat Model

Metabolite Biomarkers for Early Ischemic Hypoxic Encephalopathy: An Experimental Study Using the NeoBase 2 MSMS Kit in a Rat Model

Metabolite Biomarkers for Early Ischemic–Hypoxic Encephalopathy: An Experimental Study Using the NeoBase 2 MSMS Kit in a Rat Model

Contact Info

Product

Resources

About